文献速递胸部PETCT

氟脱氧葡萄糖PET/CT与成纤维细胞活化蛋白抑制剂PET/CT评估肺癌性能的系统综述与荟萃分析

Performance of [18F]FDG PET/CT versus FAPI PET/CT for lung cancer assessment: a systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2023-08-17

该系统综述与荟萃分析比较了氟脱氧葡萄糖PET/CT与成纤维细胞活化蛋白抑制剂PET/CT在肺癌原发灶、淋巴结及远处转移评估中的诊断性能。结果显示,成纤维细胞活化蛋白抑制剂PET/CT检测转移灶的敏感度为0.99(95%CI 0.90-1.00),高于氟脱氧葡萄糖PET/CT的0.77(95%CI 0.66-0.85);因缺乏足够真阴性信息,两者特异度均无法评估。作者认为成纤维细胞活化蛋白抑制剂PET/CT可作为原发灶、淋巴结转移及远处转移评估的替代影像方法。

要点

  • 成纤维细胞活化蛋白抑制剂PET/CT检测肺癌转移灶敏感度0.99,高于氟脱氧葡萄糖PET/CT的0.77。
  • 原发灶检测敏感度两者相近:成纤维细胞活化蛋白抑制剂0.98,氟脱氧葡萄糖0.99。
  • 因缺乏足够真阴性信息,两种检查方法的特异度均无法评估。

核心结论

  • 在肺癌转移灶诊断中,成纤维细胞活化蛋白抑制剂PET/CT的敏感度高于氟脱氧葡萄糖PET/CT;成纤维细胞活化蛋白抑制剂PET/CT可考虑作为评估原发肿瘤、淋巴结转移和远处转移的替代影像方法。

研究设计与样本

  • 系统综述与荟萃分析,检索Cochrane Library、Embase和PubMed/MEDLINE自建库至2022年11月1日的文献,纳入评估成纤维细胞活化蛋白抑制剂PET/CT与氟脱氧葡萄糖PET/CT在肺癌患者中应用的研究,采用诊断准确性研究质量评价工具第2版评估偏倚风险,并使用随机变量模型分析两种影像检查的诊断试验。

诊断标准与关键数值

  • 成纤维细胞活化蛋白抑制剂PET/CT检测原发肺癌病灶的敏感度为0.98(95%CI:0.88-1.00),氟脱氧葡萄糖PET/CT为0.99(95%CI:0.74-1.00)。检测转移灶(淋巴结转移和远处转移)时,成纤维细胞活化蛋白抑制剂PET/CT敏感度为0.99(95%CI:0.90-1.00),氟脱氧葡萄糖PET/CT为0.77(95%CI:0.66-0.85)。因缺乏足够的真阴性相关信息,两种影像方法的特异度均无法评估。

临床应用与阅片要点

  • 作者认为,成纤维细胞活化蛋白抑制剂PET/CT可考虑作为评估肺癌原发肿瘤、淋巴结转移和远处转移的替代影像方法。

局限性

  • 因缺乏足够的真阴性相关信息,两种影像方法的特异度均无法评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This article aims to compare the diagnostic performance of 18-fluorodeoxyglucose ([18F]FDG) PET/CT and fibroblast activating protein inhibitor (FAPI) PET/CT in the assessment of primary tumors, lymph nodes, and distant metastases in lung cancer patients.

METHODS: A systematic search was conducted on the Cochrane Library, Embase, and PubMed/MEDLINE databases from inception until November 1, 2022. Included studies assessed the use of FAPI PET/CT and [18F]FDG PET/CT in patients with lung cancer. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool was used to evaluate the risk of bias. A random variable model was used to analyze the diagnostic tests of the two imaging modalities.

RESULTS: The sensitivity of FAPI PET/CT in detecting primary lung cancer lesions was 0.98 (95% CI: 0.88-1.00), while the sensitivity of [18F]FDG PET/CT was 0.99 (95% CI: 0.74-1.00). For the detection of metastatic lesions (lymph node metastases and distant metastases), FAPI PET/CT had a sensitivity of 0.99 (95% CI: 0.90-1.00), while the sensitivity of [18F]FDG PET/CT was 0.77 (95% CI: 0.66-0.85). However, the specificity of the two imaging modalities could not be assessed due to the lack of sufficient information on pertinent true negatives.

CONCLUSION: In the diagnosis of metastatic lung cancer lesions, FAPI PET/CT demonstrated a higher sensitivity compared to [18F]FDG PET/CT. Therefore, FAPI PET/CT may be considered an alternative imaging modality for the assessment of primary lung cancer tumors, lymph node metastases, and distant metastases.

CLINICAL RELEVANCE STATEMENT: FAPI may be an alternative to [18F]FDG in the assessment of primary lung cancer tumors, lymph node metastases, and distant metastases, which plays a very important role in treatment.

KEY POINTS: • This article is to compare the performance of [18F]FDG PET/CT with FAPI PET/CT in the assessment of primary tumors, lymph nodes, and distant metastases in lung cancer. • However, FAPI PET/CT has a higher sensitivity for the diagnostic assessment of metastatic lung cancer lesions.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yang Q, Huang D, Wu J, et al. Performance of [18F]FDG PET/CT versus FAPI PET/CT for lung cancer assessment: a systematic review and meta-analysis. Eur Radiol. 2023. PMID: 37589901. doi:10.1007/s00330-023-10013-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。